Summary of Currently Available Mouse Models / Amilto and Namiko Ito and Kimie Niimi and Takashi Ami and Eiki Takahashi1: |
Introduction / 1.1: |
Origin and History of Laboratory Mice / 1.2: |
Laboratory Mouse Strains / 1.3: |
Wild-Derived Mice / 1.3.1: |
Inbred Mice / 1.3.2: |
Hybrid Mice / 1.3.3: |
Outbred Stocks / 1.3.4: |
Closed Colony / 1.3.5: |
Congenic Mice / 1.3.6: |
Mutant Mice / 1.4: |
Spontaneous / 1.4.1: |
Transgenesis / 1.4.2: |
Targeted Mutagenesis / 1.4.3: |
Inducible Mutagenesis / 1.4.4: |
Cre-loxP System / 1.4.5: |
CRISPR/Cas9 System / 1.4.6: |
Resources of Laboratory Strains / 1.5: |
Germ-Free Mice / 1.6: |
Gnotobiotic Mice / 1.7: |
Specific Pathogen-Free Mice / 1.8: |
Immunocompetent and Immunodeficient Mice / 1.9: |
Mouse Health Monitoring / 1.10: |
Production and Maintenance of Mouse Colony / 1.11: |
Production Planning / 1.11.1: |
Breeding Systems and Mating Schemes / 1.11.2: |
Mating / 1.12: |
Gestation Period / 1.13: |
Parturition / 1.14: |
Parental Behavior and Rearing Pups / 1.15: |
Growth of Pups / 1.16: |
Reproductive Lifespan / 1.17: |
Record Keeping and Colony Organization / 1.18: |
Animal Identification / 1.19: |
Animal Models in Preclinical Research / 1.20: |
References |
General Notes of Chemical Administration to Live Animals / Ami Ito and Nomiko Ito and Takashi Arai and Eiki Takahashi and Kimie Niimi2: |
Restraint / 2.1: |
One-Handed Restraint / 2.2.1: |
Two-Handed Restraint / 2.2.2: |
Substances / 2.3: |
Substance Characteristics / 2.3.1: |
Vehicle Characteristics / 2.3.2: |
Frequency and Volume of Administration / 2.3.3: |
Needle Size / 2.3.4: |
Anesthesia / 2.4: |
Inhaled Agents / 2.4.1: |
Injectable Agents / 2.4.2: |
Euthanasia / 2.5: |
Administration / 2.6: |
Enteral Administration / 2.6.1: |
Oral Administration / 2.6.1.1: |
Intragastric Administration / 2.6.1.2: |
Parenteral Administration / 2.6.2: |
Subcutaneous Administration / 2.6.2.1: |
Intraperitoneal Administration / 2.6.2.2: |
Intravenous Administration / 2.6.2.3: |
Intramuscular Administration / 2.6.2.4: |
Intranasal Administration / 2.6.2.5: |
Intradermal Administration / 2.6.2.6: |
Epicutaneous Administration / 2.6.2.7: |
Intratracheal Administration / 2.6.2.8: |
Inhalational Administration / 2.6.2.9: |
Retro-orbital Administration / 2.6.2.10: |
Optical-Based Detection in Live Animals / Mikako Ogawa and Hideo Takakura3: |
Basics of Luminescence / 3.1: |
Appropriate Wavelengths for Live Animal Imaging / 3.1.2: |
Advantages and Disadvantages of In Vivo Optical Imaging / 3.1.3: |
Fluorescence Imaging in Live Animals / 3.2: |
Fluorescent Molecules for Live Animal Imaging / 3.2.1: |
How to Detect Fluorescence in Live Animals? / 3.2.2: |
Activatable Probes / 3.2.3: |
Microscope / 3.2.4: |
Application of Fluorescence Imaging to Drug Development / 3.2.5: |
Luminescence Imaging in Live Animals / 3.3: |
Luminescence Systems for Live Animal Imaging / 3.3.1: |
Firefly/Beetle Luciferin-Luciferase System / 3.3.1.1: |
Coelenterazine-Dependent Luciferase System / 3.3.1.2: |
Chemiluminescence System / 3.3.1.3: |
How to Detect Luminescence in Live Animals? / 3.3.2: |
Luciferase-Based Bioluminescence Probes for In Vivo Imaging / 3.3.3: |
Summary / 3.4: |
Ultrasound Imaging in Live Animals / Francesco Faita4: |
High-Frequency Ultrasound Imaging / 4.1: |
Ultrasound Contrast Agents / 4.3: |
Photoacoustic Imaging / 4.4: |
Preclinical Applications / 4.5: |
Cardiovascular / 4.5.1: |
Oncology / 4.5.2: |
Developmental Biology / 4.5.3: |
Positron Emission Tomography (PET) Imaging in Live Animals / Xiaowei Ma and Zhen Cheng5: |
Brief History of PET / 5.1: |
Principles of PET / 5.3: |
Small-Animal PET Scanners / 5.4: |
PET Imaging Tracers / 5.5: |
Metabolic Probe / 5.5.1: |
Specific Receptor Targeting Probe / 5.5.2: |
Gene Expression / 5.5.3: |
Specific Enzyme Substrate / 5.5.4: |
Microenvironment Probe / 5.5.5: |
Biological Processes / 5.5.6: |
Perfusion Probes / 5.5.7: |
Nanoparticles / 5.5.8: |
PET in Animal Imaging / 5.6: |
PET in Oncology Model / 5.6.1: |
Cancer Diagnosis / 5.6.1.1: |
Personal Treatment Screening / 5.6.1.2: |
Therapeutic Effect Monitoring / 5.6.1.3: |
Radiotherapy Planning / 5.6.1.4: |
Drug Discovery / 5.6.1.5: |
PET in Cardiology Model / 5.6.2: |
PET in Neurology Model / 5.6.3: |
PET Imaging in Other Disease Models / 5.6.4: |
PET Image Analysis / 5.7: |
Outlook for the Future / 5.8: |
Reference |
Single-Photon Emission Computed Tomographic Imaging in Live Animals / Yusuke Yagi and Hidekazu Kawashima and Kenji Arimitsu and Koki Hasegawa and Hiroyuki Kimura6: |
SPECT Devices Used in Small Animals / 6.1: |
Innovative Preclinical Full-Body SPECT Imager for Rats and Mice: ¿-CUBE / 6.2.1: |
Innovative Preclinical Full-Body PET Imager for Rats and Mice: ß-CUBE / 6.2.2: |
Innovative Preclinical Full-Body CT Imager for Rats and Mice: X-CUBE / 6.2.3: |
Animal Monitoring: Its Importance and Overview of MOLECUBES's Integrated Solution to Advance Physiological Monitoring / 6.2.4: |
Selected Applications Acquired on the CUBES / 6.2.5: |
SPECT Imaging with ¿-CUBE / 6.2.5.1: |
PET Imaging with ß-CUBE / 6.2.5.2: |
CT Imaging with X-CUBE / 6.2.5.3: |
Characteristics of SPECT Radionuclides and SPECT Imaging Probes / 6.3: |
Characteristics of SPECT Radionuclides / 6.3.1: |
Characteristics of SPECT Imaging Probes / 6.3.2: |
Radiolabeling / 6.4: |
Characteristic of Radiolabeling / 6.4.1: |
Radiolabeling with Technetium-99m / 6.4.2: |
Radiolabeling with Iodine-123 and Iodine-131 / 6.4.3: |
Radioactive Iodine Labeling for Small Molecular Compounds / 6.4.4: |
Aromatic Electrophilic Substitution Reaction / 6.4.5: |
In Vivo Imaging of Disease Models / 6.5: |
Imaging of Central Nervous System Disease / 6.5.1: |
Alzheimer's Disease / 6.5.1.1: |
Parkinson's Disease / 6.5.1.2: |
Cerebral Ischemia / 6.5.1.3: |
Imaging of Cardiovascular Disease / 6.5.2: |
Atherosclerotic Plaque / 6.5.2.1: |
Myocardial Ischemia / 6.5.2.2: |
Imaging of Cancer / 6.5.2.3: |
Conclusions / 6.6: |
Radiotherapeutic Applications / Koki Hasegawa and Hidekazu Kawashima and Yusuke Yagi and Hiroyuki Kimura7: |
Radionuclide Therapy in Tumor-Bearing Mice / 7.1: |
Radiotherapy with ß-Emitting Nuclides / 7.2.1: |
Radiotherapy Using ¿-Emitting Nuclides / 7.2.2: |
Radiolabeling Strategy / 7.3: |
Labeled Target Compounds / 7.3.1: |
211At-Labeled Compounds / 7.3.2: |
Chelating Agents for 90Y, 177Lu, 225Ac, 213Bi / 7.3.3: |
Peptides for Radionuclide Therapy / 7.3.4: |
Octreotate (TATE) and [Tyr3]-Octreotide (TOC) / 7.3.4.1: |
NeoBOMB1 / 7.3.4.2: |
Pentixather / 7.3.4.3: |
PSMA-617 / 7.3.4.4: |
Minigastrin / 7.3.4.5: |
Antibodies for Radionuclide Therapy / 7.3.5: |
Lintuzumab / 7.3.5.1: |
Rituximab / 7.3.5.2: |
Trastuzumab / 7.3.5.3: |
Examples of Radiotherapeutic Agents and Target Diseases / 7.3.6: |
Radiotheranostics / 7.4: |
Radiotheranostics Probe / 7.4.1: |
Our Approach to Radiotheranostic Probe Development / 7.4.2: |
Expectations and Challenges in Radiotheranostics / 7.4.3: |
Boron Neutron Capture Therapy (BNCT) / 7.4.4: |
Current Status of BNCT Drugs / 7.4.5: |
4-Borono-L-Phenylalanine (BPA) / 7.4.5.1: |
Sodium Borocaptate (BSH) / 7.4.5.2: |
Conclusion / 7.5: |
Metabolic Glycan Engineering in Live Animals: Using Bio-orthogonal Chemistry to Alter Cell Surface Glycans / Danielle H. Dube and Daniel A. Williams8: |
Overview of Metabolic Glycan Engineering / 8.1: |
Origin of Metabolic Glycan Engineering / 8.2.1: |
Expansion of the Methodology to Include Unnatural Functional Groups and Bio-orthogonal Elaboration / 8.2.2: |
Bio-orthogonal Chemistries that Alter Cell Surface Glycans / 8.3: |
Bio-orthogonal Chemistries Amenable to Deployment in Live Animals / 8.3.1: |
Bio-orthogonal Chemistries Amenable to Deployment on Cells / 8.3.2: |
Permissive Carbohydrate Biosynthetic Pathways / 8.4: |
Deployment of Unnatural Monosaccharides in Mammalian Cells / 8.4.1: |
Unnatural Sugars that Label Glycans on Bacterial Cells / 8.4.2: |
Cell- and Tissue-Specific Delivery of Unnatural Sugars / 8.5: |
Harness Inherent Differences in Carbohydrate Biosynthesis / 8.5.1: |
Metabolically Label Cells Ex vivo Before Introducing Them In vivo / 8.5.2: |
Label Tissues or Organs In vivo Before Analyzing them Ex vivo / 8.5.3: |
Employ Tissue-Specific Enzymes to Release Monosaccharide Substrates / 8.5.4: |
Deliver Monosaccharide Substrates via Liposomes / 8.5.5: |
Use Tissue-Specific Transporters to Induce Monosaccharide Uptake / 8.5.6: |
Applications of Metabolic Glycan Labeling in Mice / 8.6: |
Imaging Glycans in Mice / 8.6.1: |
Covalent Delivery of Therapeutics in Mice / 8.6.2: |
Beyond Mice: Metabolic Glycan Engineering in Diverse Animals / 8.7: |
Zebra Fish / 8.7.1: |
Worms / 8.7.2: |
Plants / 8.7.3: |
Conclusions and Future Outlook / 8.8: |
Metabolic Glycan Engineering Offers a Test Bed for Bio-orthogonal Chemistries / 8.8.1: |
New Bio-orthogonal Reactions Could Transform the Field / 8.8.2: |
Basic Questions About Glycans Within Living Systems Remain Unanswered / 8.8.3: |
Acknowledgments |
In Vivo Bioconjugation Using Bio-orthogonal Chemistry / Maksim Royzen and Nathan Yee and Jose M. Mejia Oneto9: |
IEDDA Chemistry Between trans-Cyclooctene and Tetrazine / 9.1: |
Synthesis of New Tetrazines and Characterization of Their Reactivity / 9.1.2: |
Second Generation of IEDDA Reagents / 9.1.3: |
Bond-cleaving Bio-orthogonal "Click-to-Release" Chemistry / 9.1.4: |
In Vivo Applications of IEDDA Chemistry / 9.2: |
Pretargeting Approach for Cell Imaging / 9.2.1: |
Pretargeting Approach for In Vivo Imaging / 9.2.2: |
Application of the Pretargeting Strategy for In Vivo Radio Imaging / 9.2.3: |
In Vivo Drug Activation Using Bond-cleaving Bio-orthogonal Chemistry / 9.2.4: |
Reloadable Materials Allow Local Prodrug Activation / 9.2.5: |
Reloadable Materials Allow Local Prodrug Activation Using IEDDA Chemistry / 9.2.6: |
Controlled Activation of siRNA Using IEDDA Chemistry / 9.2.7: |
Future Outlook / 9.3: |
In Vivo Targeting of Endogenous Proteins with Reactive Small Molecules / Naoyo Shindo and Akio Ojida10: |
Ligand-Directed Chemical Ligation / 10.1: |
Ligand-Directed Tosyl Chemistry / 10.2.1: |
Ligand-Directed Acyl Imidazole Chemistry / 10.2.2: |
Other Chemical Reactions for Endogenous Protein Labeling / 10.2.3: |
Labeling Chemistry of Targeted Covalent Inhibitors / 10.3: |
Michael Acceptors / 10.3.1: |
Haloacetamides / 10.3.2: |
Activated Esters, Amides, Carbamates, and Ureas / 10.3.3: |
Sulfur(VI) Fluorides / 10.3.4: |
Other Warheads and Reactions / 10.3.5: |
In Vivo Metal Catalysis in Living Biological Systems / Kenward Vong and Katsunori Tanaka10.4: |
Metal Complex Catalysts / 11.1: |
Protein Decaging / 11.2.1: |
Protein Bioconjugation / 11.2.2: |
Small Molecule - Bond Formation / 11.2.3: |
Small Molecule - Bond Cleavage / 11.2.4: |
Artificial Metalloenzymes / 11.3: |
ArMs Utilizing Naturally Occurring Metals / 11.3.1: |
ArMs Utilizing Abiotic Transition Metals / 11.3.2: |
Concluding Remarks / 11.4: |
Chemical Catalyst-Mediated Selective Photo-oxygenation of Pathogenic Amyloids / Youhei Sohma and Motomu Kanai12: |
Catalytic Photo-oxygenation of Aß Using a Flavin-Peptide Conjugate / 12.1: |
On-Off Switchable Photo-oxygenation Catalysts that Sense Higher Order Amyloid Structures / 12.3: |
Near-Infrared Photoactivatable Oxygenation Catalysts: Application to Amyloid Disease Model Mice / 12.4: |
Closing Remarks / 12.5: |
Nanomedicine Therapies / Patrícia Figueiredo and Flavia Fontana and Hélder A. Santos13: |
Engineering Nanoparticles for Therapeutic Applications / 13.1: |
Physicochemical Properties of NPs / 13.2.1: |
Surface Functionalization / 13.2.2: |
Stimuli-Responsive Nanomaterials / 13.2.3: |
Route of Administration / 13.2.4: |
Nanomedicine Platforms / 13.3: |
Lipidic Nanoplatforms / 13.3.1: |
Polymer-Based Nanoplatforms / 13.3.2: |
Inorganic Nanoplatforms / 13.3.3: |
Biomimetic Cell-Derived Nanoplatforms / 13.3.4: |
Photoactivatable Targeting Methods / Xiangzhao Ai and Ming Hu and Bengang Xing13.4: |
UV Light-Responsive Theranostics / 14.1: |
UV Light-Triggered Photocaged Strategy / 14.2.1: |
UV Light-Mediated Photoisomerization Strategy / 14.2.2: |
Visible Light-Responsive Theranostics / 14.3: |
Near-Infrared (NIR) Light-Responsive Theranostics / 14.4: |
NIR Light-Mediated Drug Delivery Approach / 14.4.1: |
NIR Light-Mediated Photodynamic Therapy (PDT) Approach / 14.4.2: |
NIR Light-Mediated Photothermal Therapy (PTT) Approach / 14.4.3: |
Conclusion and Prospects / 14.5: |
Acknowledgment |
Photoactivatable Drug Release Methods from Liposomes / Hailey I. Kilian and Dyego Miranda and Jonathan F. Lovell15: |
Light-Sensitive Liposomes / 15.1: |
Mechanisms of Light-Triggered Release from Liposomes / 15.2: |
Light-Induced Oxidation / 15.2.1: |
Photocrosslinking / 15.2.2: |
Photoisomerization / 15.2.3: |
Photocleavage / 15.2.4: |
Photothermal Release / 15.2.5: |
Peptide Targeting Methods / Ruei-Min Lu and Chien-Hsun Wu and Ajay V. Patil and Han-Chung Wu16: |
Identification of Targeting Peptides / 16.1: |
Natural Ligands and Biomimetics / 16.2.1: |
Phage Display Peptide Library Screening / 16.2.2: |
Synthetic Peptide Library Screening / 16.2.3: |
Therapeutic Applications of Targeting Peptides / 16.3: |
Therapeutic Peptides / 16.3.1: |
Naturally Occurring Peptides / 16.3.1.1: |
Peptide Conjugates / 16.3.1.2: |
Drug Delivery / 16.3.2: |
Peptide-Drug Conjugates / 16.3.2.1: |
Peptide-Targeted Nanoparticles / 16.3.2.2: |
Molecular Imaging Mediated by Targeting Peptides / 16.4: |
Optical Imaging / 16.4.1: |
Targeting Peptides for Tumor Imaging / 16.4.1.1: |
Integrin ¿vß3 - RGD Tripeptide Targeting Probes: / 16.4.1.2: |
Near-Infrared Imaging / 16.4.1.3: |
Positron Emission Tomography / 16.4.2: |
Magnetic Resonance Imaging / 16.4.3: |
Summary and Future Perspectives / 16.5: |
Glycan-Mediated Targeting Methods / Kenward Vong and Katsunori Tanaka and Koichi Fukase17: |
Liver and Liver-Based Disease Targeting / 17.1: |
Parenchymal Cell Targeting / 17.2.1: |
Nonparenchymal Cell Targeting / 17.2.2: |
Immune System Targeting / 17.3: |
Alveolar Macrophage Targeting / 17.3.1: |
Peritoneal Macrophage Targeting / 17.3.2: |
Dendritic Cell Targeting / 17.3.3: |
Brain Macrophage Targeting / 17.3.4: |
Bacterial Cell Targeting / 17.4: |
Cancer Targeting / 17.5: |
Natural Monosaccharide-Based Methods / 17.5.1: |
Synthetic Sugars / 17.5.2: |
Complex Glycan Scaffold / 17.5.3: |
Index / 17.6: |